Patient-reported outcomes and quality of life with sunitinib versus placebo for pancreatic neuroendocrine tumors: results from an international phase III trial.
Vinik, A Bottomley, A Korytowsky, B Bang, Y Raoul, J Valle, Juan W Metrakos, P Hörsch, D Mundayat, R Reisman, A
Vinik, A
Bottomley, A
Korytowsky, B
Bang, Y
Raoul, J
Valle, Juan W
Metrakos, P
Hörsch, D
Mundayat, R
Reisman, A
Citations
Altmetric:
Abstract
The objective of this analysis was to compare patient-reported outcomes and health-related quality of life (HRQoL) in a pivotal phase III trial of sunitinib versus placebo in patients with progressive, well-differentiated pancreatic neuroendocrine tumors (NCT00428597).
Description
Date
2016-12
Publisher
Collections
Keywords
Type
Article
Citation
Patient-reported outcomes and quality of life with sunitinib versus placebo for pancreatic neuroendocrine tumors: results from an international phase III trial. 2016, 11 (6):815-824 Target Oncol